| Document |
Document Title |
|
WO/2022/035405A1 |
The invention relates to a drug and its method of manufacture, which allows to reduce hypertension and treat type 2 diabetes mellitus by using the drug as a dipeptidyl peptidase-4 (DPP-4) inhibitor. The rate of hypoglycemia of the drug i...
|
|
WO/2022/036111A1 |
The present disclosure relates to methods for decreasing or increasing one or more biomarkers by administering PDE9 pharmaceutical compositions comprising 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]
-3-tetrahydropyran-4-...
|
|
WO/2022/033480A1 |
A liquid preparation, comprising a recombinant hEPO-Fc fusion protein, a buffer solution, and a stabilizer. The liquid preparation may further comprise other adjuvant materials. Also provided is a use of the liquid preparation in prepara...
|
|
WO/2022/033303A1 |
The present invention relates to a benzylamine derivative, a preparation method therefor and use thereof, and in particular, to a benzylamine derivative as represented by general formula (I), or a pharmaceutically acceptable stereoisomer...
|
|
WO/2022/032997A1 |
An inhibitor, an inhibitor composition, and a drug and an application thereof. Disclosed is that zkscan3 interacts with GATA1 and inhibits transcriptional activity of GATA1, thereby affecting erythropoiesis. Also disclosed is that a zksc...
|
|
WO/2022/032484A1 |
Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof....
|
|
WO/2022/036188A1 |
The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be u...
|
|
WO/2022/034595A1 |
The present invention relates to ADAMTS-13 mutants and/or variant/s that display resistance to tPA cleavage and/or inactivation. The present disclosure further provides fibrinolytic compounds, compositions, combined compositions and kits...
|
|
WO/2022/029497A1 |
Disclosed is ularitide for use in methods for treating refractory ascites, comprising subcutaneously administering ularitide to a patient in need thereof via an implantable drug depot composition or via an infusion pump system, wherein t...
|
|
WO/2022/027953A1 |
Disclosed is the use of C188-9, Venetoclax, and Bumetanide in a drug for fibrotic diseases. From a clinical view, an RNA recognition motif (RRM) region of the LARP6 protein is used as a docking target, and is subjected to computer virtua...
|
|
WO/2022/028457A1 |
Disclosed are an siRNA for inhibiting the expression of blood coagulation factor XI, and a composition and the medical use thereof. Particularly, the siRNA comprises a sense strand and an antisense strand, wherein the sense strand contai...
|
|
WO/2022/031735A1 |
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods o...
|
|
WO/2022/027898A1 |
Provided is use of a FGFR2b inhibitory molecule in preparation of a medicament for treating PAF-mediated diseases. The use is on the basis of the research results obtained by the inventors that FGF‐7 can induce the production of platel...
|
|
WO/2022/027237A1 |
An application of quizartinib as a necroptosis inhibitor. An application of quizartinib as an RIPK1-dependent cell necroptosis inhibitor. An application of quizartinib as a cell necroptosis initiation marker phosphorylation inhibitor, th...
|
|
WO/2022/031686A1 |
The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-l-methyl-4H- benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating thrombocythemia.
|
|
WO/2022/028547A1 |
Provided in the present invention are a class of bifunctional compounds for targeting and degrading an IRAK4 kinase protein, a pharmaceutical composition and a preparation method therefor. The compound of the present invention can not on...
|
|
WO/2022/028347A1 |
An optically active 2-hydroxyltetrahydrothienopyridine derivative, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the compound of formula (I) or the salt and...
|
|
WO/2022/027240A1 |
An application of primidone as a RIPK1 inhibitor. Primidone can be used as a RIPK1 inhibitor to treat amyotrophic lateral sclerosis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, ischemia-reperfusion injury, ischemic s...
|
|
WO/2022/029499A1 |
Disclosed is a method for treating refractory ascites comprising administering ularitide to a patient in need thereof continuously for a time period between about 2 hours and about 168 hours. The method may further comprise bolus adminis...
|
|
WO/2022/026631A1 |
The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
|
|
WO/2022/025231A1 |
Provided are: a novel method for performing nutrition supply while suppressing the symptoms of refeeding syndrome in patients in a low nutritional state; and a nutrition formulation which can be used in said method. Provided is a nutriti...
|
|
WO/2022/026339A1 |
The present invention provides, inter alia, compounds capable of inhibiting NF-KB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein. Also provided are compositions, methods and kits for t...
|
|
WO/2022/025783A1 |
The invention relates to genetic engineering, biotechnology and medicine; more specifically, the present invention provides stimulation of angiogenesis, regeneration of nerve fibers of blood vessels and regeneration of skeletal muscle by...
|
|
WO/2022/016343A1 |
A use of a composition for preventing and/or eliminating platelet aggregation in a blood sample in ex-vivo blood test. The composition comprises at least one ammonium ion-containing compound. A reagent comprising the compound and used fo...
|
|
WO/2022/016345A1 |
Disclosed is an application of a composition for preventing and/or eliminating platelet aggregation in an in vitro blood sample. The composition comprises at least one compound selected from the group consisting of formula (I) and a salt...
|
|
WO/2022/020424A1 |
Provided herein are compositions and methods for activating pyruvate kinase (e.g., in a subject). In particular, provided herein are compositions and methods for treating a disease or condition (e.g., eye disease, blood disorders, or can...
|
|
WO/2022/018156A1 |
The present invention is directed to Factor XIa inhibitors, tautomers, stereoisomers, isotopologues, and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions containing said compounds and the use of said co...
|
|
WO/2022/017532A1 |
The present invention relates to a c-Src SH3 RT-loop as a target for resisting thrombus. Specifically, provided in the present invention is the use of a c-Src SH3 RT-loop antagonist for preparing a composition or a preparation, wherein t...
|
|
WO/2022/020546A1 |
The present invention is directed to 3-(1H-imidazol-2-yl)-2,3,8,8a-tetrahydroindolizin-5(1H)-one derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compou...
|
|
WO/2022/018256A1 |
The invention relates to a compound of general formula (III'), or one of the pharmaceutically acceptable salts thereof, for use of same in the treatment of haemophilia in a patient, in particular for restoring coagulation in the plasma o...
|
|
WO/2022/018450A1 |
The present invention relates to crystalline forms of vadadustat, including a crystalline vadadustat anhydrate and a crystalline vadadustat urea molecular complex. The present invention also relates to processes for their preparation and...
|
|
WO/2022/013052A1 |
The present invention relates to compounds comprising 2-hydroxy-6-((2-(1-isopropyl-1H- pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (INN: voxelotor) and 2,5-dihydroxybenzoic acid and to crystalline forms thereof. Also provided are proc...
|
|
WO/2022/016097A1 |
Provided are methods for reducing substance consumption by subjects. In some embodiments, the presently disclosed methods include administering to a subject in need thereof a composition that includes an effective amount of an inhibitor ...
|
|
WO/2022/014704A1 |
The present invention provides a novel VEGF-binding peptide or a compound including a novel VEGF-binding peptide structure. For example, the present invention provides a compound represented by the following formula (I) (where peptide A ...
|
|
WO/2022/014122A1 |
The primary problem of the present invention is to provide a novel pharmaceutical composition. The present invention relates to a pharmaceutical composition containing a cerium compound as an active ingredient.
|
|
WO/2022/012509A1 |
A compound as a BTK inhibitor or an HER2 inhibitor, a preparation method therefor, and a use thereof. The compound comprises a structure as shown in formula II or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mix...
|
|
WO/2022/013276A1 |
The present invention relates to an aqueous pharmaceutical composition comprising the P2Y12 receptor antagonist 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperaz
ine-1-car...
|
|
WO/2022/013187A1 |
A tablet comprising at least 60% w/w of voxelotor and at least 10% w/w of low-substituted hydroxy propyl cellulose. Process for the preparation of a tablet comprising the process steps of blending voxelotor with low-substituted hydroxypr...
|
|
WO/2022/013604A1 |
Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.
|
|
WO/2022/012510A1 |
A compound serving as a BTK inhibitor, a preparation method therefor, and a use thereof. The compound has a structure represented by formula I, or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture thereof, or ...
|
|
WO/2022/007007A1 |
Use of colchicine, an application of the colchicine as a drug for treating hyperphosphatemia caused by chronic renal insufficiency and uremia, and an application of the colchicine as a drug for inhibiting phosphorus absorption of intesti...
|
|
WO/2022/000572A1 |
Provided is a new method for activating transcription of a gamma-globin gene. The method uses a single-stranded oligonucleotide (ssODN) containing GATA or an antisense complementary sequence TATC thereof as guidance information, and perf...
|
|
WO/2022/002880A1 |
Vitamin K-dependent Protein S (PS) is a natural anticoagulant acting as a non-enzymatic cofactor for both activated protein C (APC) and tissue factor pathway inhibitor (TFPI). The inventors identify an anti-PS nanobody that very surprisi...
|
|
WO/2022/002142A1 |
The present application describes tetrahydroisoquinoline compounds as PRMT5 inhibitors and pharmaceutically acceptable salts thereof. Said compounds have the structure of formula (I), and have substituents and structural features describ...
|
|
WO/2022/004816A1 |
Provided is a cranial nerve disorder therapeutic agent that includes, as an active ingredient, a culture supernatant of tissue cells derived from a fetal appendage.
|
|
WO/2022/003175A1 |
The present invention relates to an oil-in-water emulsion containing N-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)dodecanamid
e or a derivative, solvate, hydrate, or prodrug thereof or a pharmaceutically acceptable salt thereof, and ...
|
|
WO/2022/002233A1 |
The present invention relates to the field of medical biology, and discloses a single domain antibody against a coagulation factor XI (FXI) and a derivative protein thereof. In particular, the present invention discloses a coagulation fa...
|
|
WO/2022/004864A1 |
The present disclosure relates to: a marker for concentrating or isolating hematopoietic stem cells and a method for using the same; cells or a cell aggregate isolated or concentrated by the marker; a method for using the cells or cell a...
|
|
WO/2022/000046A1 |
The present application is directed to a liquid formulation comprising at least 100mg/ml of a protein comprising an antigen binding domain that binds to FXII (and/or an activated form thereof), an organic buffer, a non-ionic surfactant a...
|
|
WO/2022/002249A1 |
Provided are an anti-FXI/FXIa antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof, as well as a pharmaceutical composition comprising the anti-FXI/FXIa antibody or the antigen-binding fragment thereof, and a m...
|
